Key terms
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATNM news
Mar 14
9:00am ET
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and P3 Health Partners (PIII)
Mar 11
10:15am ET
Buy Rating Affirmed: Strategic Advances and Clinical Potential Bolster Actinium Pharmaceuticals’ Outlook
Mar 11
7:31am ET
Actinium Pharmaceuticals launches Actinium-225 focused strategic initative
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 27
7:45am ET
Buy Rating Justified by Actinium Pharmaceuticals’ Iomab-B Clinical and Commercial Promise
Feb 27
7:37am ET
Iomab-B’s Breakthrough Potential in AML Treatment Bolsters Buy Rating for Actinium Pharmaceuticals
Feb 26
7:42am ET
Actinium Pharmaceuticals reported new analyses from Phase 3 SIERRA trial
Feb 24
1:45pm ET
Actinium Pharmaceuticals: A Strong Buy on Revolutionary Radiopharma and ADC Platform Potential
Feb 23
11:15am ET
Buy Rating Affirmed: Actinium Pharmaceuticals’ Iomab-B Shows Promising Efficacy and Market Potential
Feb 23
7:51am ET
Actinium Pharmaceuticals reports results from Phase 3 SIERRA trial of Iomab-B
Feb 17
7:45am ET
Buy Rating Affirmed: Actinium Pharmaceuticals Poised for Growth in Innovative Cancer Treatments
Feb 16
7:55am ET
Buy Rating Affirmed for Actinium Pharmaceuticals Amidst Promising Pipeline and Market Expansion Opportunities
Jan 03
2:25pm ET
Actinium Pharmaceuticals: A Strong Buy on Robust Financials and Promising Clinical Advances
No recent news articles are available for ATNM
No recent press releases are available for ATNM
ATNM Financials
Key terms
Ad Feedback
ATNM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATNM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range